Europe Biologics Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Europe Biologics Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Europe Biologics Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Europe Biologics Market Regional Analysis

6.2 Europe Biologics Market Revenue 2021-2031 (US$ Million)

6.3 Europe Biologics Market Forecast Analysis

7. Europe Biologics Market Analysis – by Product

7.1 Monoclonal Antibodies

7.1.1 Overview
7.1.2 Monoclonal Antibodies: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.2 Vaccine

7.2.1 Overview
7.2.2 Vaccine: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.3 Recombinant Hormones/Proteins

7.3.1 Overview
7.3.2 Recombinant Hormones/Proteins: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.4 Cell and Gene Therapy

7.4.1 Overview
7.4.2 Cell and Gene Therapy: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

7.5 Others

7.5.1 Overview
7.5.2 Others: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

8. Europe Biologics Market Analysis – by Application

8.1 Cancer

8.1.1 Overview
8.1.2 Cancer: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.2 Infectious Diseases

8.2.1 Overview
8.2.2 Infectious Diseases: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.3 Autoimmune Diseases

8.3.1 Overview
8.3.2 Autoimmune Diseases: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

8.4 Others

8.4.1 Overview
8.4.2 Others: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

9. Europe Biologics Market Analysis – by Source

9.1 Mammalian and Microbial

9.1.1 Overview
9.1.2 Mammalian and Microbial: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

10. Europe Biologics Market Analysis – by Manufacturing

10.1 Outsourced and In-house

10.1.1 Overview
10.1.2 Outsourced and In-house: Europe Biologics Market – Revenue and Forecast, 2021-2031 (US$ Million)

11. Europe Biologics Market – Europe Analysis

11.1 Overview

11.2 Europe

11.2.1 Europe Biologics Market Breakdown, by Key Country, 2025 and 2031 (%)
11.2.1.1 Europe Biologics Market – Revenue and Forecast Analysis – by Country
11.2.1.1 Germany: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.1.1 Germany: Europe Biologics Market Breakdown, by Product
11.2.1.1.2 Germany: Europe Biologics Market Breakdown, by Application
11.2.1.1.3 Germany: Europe Biologics Market Breakdown, by Source
11.2.1.1.4 Germany: Europe Biologics Market Breakdown, by Manufacturing

11.2.1.2 the UK: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.2.1 the UK: Europe Biologics Market Breakdown, by Product
11.2.1.2.2 the UK: Europe Biologics Market Breakdown, by Application
11.2.1.2.3 the UK: Europe Biologics Market Breakdown, by Source
11.2.1.2.4 the UK: Europe Biologics Market Breakdown, by Manufacturing

11.2.1.3 France: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.3.1 France: Europe Biologics Market Breakdown, by Product
11.2.1.3.2 France: Europe Biologics Market Breakdown, by Application
11.2.1.3.3 France: Europe Biologics Market Breakdown, by Source
11.2.1.3.4 France: Europe Biologics Market Breakdown, by Manufacturing

11.2.1.4 Italy: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.4.1 Italy: Europe Biologics Market Breakdown, by Product
11.2.1.4.2 Italy: Europe Biologics Market Breakdown, by Application
11.2.1.4.3 Italy: Europe Biologics Market Breakdown, by Source
11.2.1.4.4 Italy: Europe Biologics Market Breakdown, by Manufacturing

11.2.1.5 Spain: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.5.1 Spain: Europe Biologics Market Breakdown, by Product
11.2.1.5.2 Spain: Europe Biologics Market Breakdown, by Application
11.2.1.5.3 Spain: Europe Biologics Market Breakdown, by Source
11.2.1.5.4 Spain: Europe Biologics Market Breakdown, by Manufacturing

11.2.1.6 Rest of Europe: Europe Biologics Market – Revenue and Forecast to 2031 (US$ Million)

11.2.1.6.1 Rest of Europe: Europe Biologics Market Breakdown, by Product
11.2.1.6.2 Rest of Europe: Europe Biologics Market Breakdown, by Application
11.2.1.6.3 Rest of Europe: Europe Biologics Market Breakdown, by Source
11.2.1.6.4 Rest of Europe: Europe Biologics Market Breakdown, by Manufacturing

12. Competitive Landscape

12.1 Heat Map Analysis

12.2 Company Positioning and Concentration

13. Industry Landscape

13.1 Overview

13.2 Market Initiative

13.3 Partnerships and Collaborations

13.4 Other Developments

14. Company Profiles

14.1 AbbVie Inc

14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments

14.2 Pfizer Inc

14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments

14.3 Samsung Biologics Co Ltd

14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments

14.4 ADMA Biologics, Inc.

14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments

14.5 Wuxi Biologics Inc

14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments

14.6 Catalent Inc

14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments

14.7 AGC Biologics AS

14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments

14.8 AstraZeneca Plc

14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments

14.9 Amgen Inc

14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments

14.10 Nitto Avecia

14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Products and Services
14.10.4 Financial Overview
14.10.5 SWOT Analysis
14.10.6 Key Developments

14.11 Quality Assistance s.a.

14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Products and Services
14.11.4 Financial Overview
14.11.5 SWOT Analysis
14.11.6 Key Developments

15. Appendix

15.1 About Business Market Insights

15.2 List of Abbreviations

Europe Biologics Market

Analysis - by Product (Monoclonal Antibodies, Vaccine, Recombinant Hormones/Proteins, Cell and Gene Therapy, and Others), Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), Source (Mammalian and Microbial), and Manufacturing (Outsourced and In-house)